Final overall survival results from a randomised, phase III study of erlotinib versus chemotherapy as first-line treatment of EGFR mutation-positive advanced non-small-cell lung cancer (OPTIMAL, CTONG-0802)C. Zhou, Changxuan You, S. Zhang et al.|Annals of Oncology|2015Cited by 467
Quality of life (QoL) analyses from OPTIMAL (CTONG-0802), a phase III, randomised, open-label study of first-line erlotinib versus chemotherapy in patients with advanced EGFR mutation-positive non-small-cell lung cancer (NSCLC)G. Chen, Changxuan You, J. Feng et al.|Annals of Oncology|2013Cited by 120
A novel large fragment deletion in PLS3 causes rare X-linked early-onset osteoporosis and response to zoledronic acidFang Lv, Ke Li, W. F. Mader et al.|Osteoporosis International|2017Cited by 32